文献速递血栓与止血

抑制蛋白Z依赖性因子Xa抑制可改善A型血友病凝血功能

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
PubMed 文献 · J Thromb Haemost · 2018-12-16

本研究在FVIII敲除血友病小鼠中评估PZ或ZPI基因缺失对凝血的影响,并观察抗PZ单克隆抗体在人血友病血浆中的作用。结果显示PZKO/FVIIIKO与ZPIKO/FVIIIKO小鼠尾静脉再出血试验凝块断裂次数高于WT/FVIIIKO小鼠,凝血酶生成相当于补充约15%重组FVIII;抗PZ单抗可使的人血友病血浆凝血酶生成增强至类似补充约15%FVIII的程度。

要点

  • PZKO/FVIIIKO与ZPIKO/FVIIIKO小鼠尾静脉再出血凝块断裂次数分别为15.2±1.1与14.7±1.2,高于WT/FVIIIKO小鼠的4.0±0.9。
  • PZKO/FVIIIKO与ZPIKO/FVIIIKO小鼠血浆凝血酶生成与补充约15%重组FVIII的FVIIIKO血浆相似。
  • 抗PZ单克隆抗体使人血友病血浆凝血酶生成增强至类似补充约15%FVIII的程度。

核心结论

  • 阻断PZ/ZPI系统可能足以改善重型血友病的表型。

研究设计与样本

  • 在麻醉小鼠尾静脉切开后15分钟内反复破坏形成的凝块,建立尾静脉再出血试验。
  • 比较WT/FVIIIKO、PZKO/FVIIIKO与ZPIKO/FVIIIKO小鼠在该模型中的表现,并检测其血浆凝血酶生成。
  • 在人人血友病血浆凝血酶生成试验中评估抗PZ单克隆抗体。

主要发现

  • 尾静脉再出血试验凝块断裂次数(均值±均值标准误):WT/FVIIIKO小鼠4.0±0.9,补充100%FVIII的WT/FVIIIKO小鼠23.8±1.1,PZKO/FVIIIKO小鼠15.2±1.1,ZPIKO/FVIIIKO小鼠14.7±1.2。
  • PZKO/FVIIIKO与ZPIKO/FVIIIKO小鼠血浆凝血酶生成与补充约15%重组FVIII的FVIIIKO血浆相似。
  • 抗PZ单克隆抗体加入人血友病血浆后,凝血酶生成增强程度与添加约15%FVIII相似。

临床怎么用

  • 原文结论认为阻断PZ/ZPI系统可能足以改善重型血友病的表型,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Suppression of the PZ/ZPI pathway may ameliorate the phenotype of severe hemophilia. SUMMARY: Background Hemostasis requires a balance between procoagulant and anticoagulant factors. Hemophiliacs bleed because of a procoagulant deficiency. Targeted reduction in the activity of endogenous anticoagulant pathways is currently being investigated as a means of improving hemostasis in hemophilia. Protein Z (PZ) is a cofactor that serves as a catalyst for PZ-dependent protease inhibitor (ZPI) inactivation of activated factor X at phospholipid surfaces. Objectives To evaluate the effects of PZ or ZPI gene deletion in hemophilic mice, and of blocking PZ in human hemophilic plasma. Methods A tail vein rebleeding assay (TVRB) was developed on the basis of the serial disruption of clots forming over a period of 15 min following tail vein laceration in an anesthetized mouse. Wild-type (WT)/FVIII knockout FVIIIKO, PZ knockout PZKO/FVIIIKO and ZPI knockout ZPIKO/FVIIIKO mice were evaluated in this model, and their plasmas were tested in thrombin generation assays. A mAb against PZ was evaluated in human hemophilic plasma thrombin generation assays. Results The numbers of clot disruptions (mean ± standard error of the mean) in the TVRB were: 4.0 ± 0.9 for WT/FVIIIKO mice; 23.8 ± 1.1 for WT/FVIIIKO mice supplemented with 100% FVIII; 15.2 ± 1.1 for PZKO/FVIIIKO mice; and 14.7 ± 1.2 for ZPIKO/FVIIIKO mice. Thrombin generation in PZKO/FVIIIKO and ZPIKO/FVIIIKO mouse plasmas was similar to that in FVIIIKO plasma supplemented with ~ 15% recombinant FVIII. A mAb against PZ added to human hemophilic plasma enhanced thrombin generation to an extent similar to the addition of ~ 15% FVIII. Conclusions Blockade of the PZ/ZPI system may be sufficient to ameliorate the phenotype of severe hemophilia.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Girard TJ, Lasky NM, Grunz K, et al. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A. J Thromb Haemost. 2018. PMID: 30451376. doi:10.1111/jth.14337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。